Navigation Links
Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance
Date:10/30/2008

81 31,810 95,827 91,148

Research and development 24,507 27,582 76,941 72,813

Marketing and sales 10,709 9,651 34,070 28,580

General and administrative 12,908 11,380 38,516 34,742

Total operating expenses 78,805 80,423 245,354 227,283

Income from operations 42,372 21,310 118,200 76,782

Interest income 4,167 3,327 12,274 8,935

Interest expense (1) - (3) 30

Other income/(expense) (1,929) 6 (647) (355)

Total other income, net 2,237 3,333 11,624 8,610

Income before income tax 44,609 24,643 129,824 85,392

Income tax expense 15,531 7,392 44,010 19,664

Net income $29,078 $17,251 $85,814 $65,728

Net income per share:

Basic $0.54 $0.32 $1.59 $1.25

Diluted $0.53 $0.31 $1.56 $1.21

Weighted average shares

outstanding:

Basic 54,084 53,221 53,882 52,661

Diluted 55,322 54,857 55,117 54,210

Gen-Probe Incorporated

Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

Nine Months Ended

September 30,

2008 2007

Operating activities:

Net income $85,814 $65,728

Adjustments to reconcile net income to ne
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Gen-Probe Announces Webcasts of Three Upcoming Investor Events
2. Gen-Probe to Webcast Two Upcoming Investor Presentations
3. Gen-Probe Announces Webcast of First Quarter 2008 Earnings Conference Call
4. Gen-Probe to Webcast Presentation at Leerink Swann Molecular Diagnostics Conference
5. Gen-Probe to Webcast Presentation at Deutsche Bank Small- and Mid-Cap Growth Conference
6. Gen-Probe to Webcast Presentation at 26th Annual JPMorgan Healthcare Conference
7. Gen-Probe to Webcast Presentation at NASDAQ 20th Investor Program
8. Jorgine Ellerbrock Joins Gen-Probe as Senior Vice President, Operations
9. 3M, Gen-Probe to Discontinue Molecular Food Testing Collaboration
10. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
11. Nuvelo Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution 2Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution 3Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 2Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 3Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 4Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 5Vivakor Announces New Acquisition Strategy 2Nucleix Researchers Discover DNA Evidence May Easily Be Falsified 4858 1Nucleix Researchers Discover DNA Evidence May Easily Be Falsified 4858 2Nucleix Researchers Discover DNA Evidence May Easily Be Falsified 4858 3Nucleix Researchers Discover DNA Evidence May Easily Be Falsified 4858 4Genetic Discovery May Improve Hepatitis C Treatment 54618 1Genetic Discovery May Improve Hepatitis C Treatment 54618 2Howard Dean and Chelsea Green Publishing Utilize iPhone Technology to engage and Mobilize Americans in Healthcare Reform Debate 54615 1Howard Dean and Chelsea Green Publishing Utilize iPhone Technology to engage and Mobilize Americans in Healthcare Reform Debate 54615 2Howard Dean and Chelsea Green Publishing Utilize iPhone Technology to engage and Mobilize Americans in Healthcare Reform Debate 54615 3Howard Dean and Chelsea Green Publishing Utilize iPhone Technology to engage and Mobilize Americans in Healthcare Reform Debate 54615 4